Diaxonhit announced consolidated earnings results for the full year ended December 31, 2013. The company reported consolidated income as of December 31, 2013 at EUR 30.5 million, an increase of 8% compared to pro forma income of EUR 28.2 million as of December 31, 2012. Total sales of in vitro diagnostic products recorded within Diaxonhit's commercial activities, reached EUR 26.3 million, an increase of 11% compared to sales of EUR 23.8 million recorded for the year 2012.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.2 EUR | +2.16% |
|
+2.90% | -13.73% |
Jun. 24 | Proteomics International Laboratories Taps French Distributor for Diabetic Kidney Disease Test | MT |
May. 08 | Eurobio Scientific: agreement with Myriad Genetics | CF |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.73% | 156M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ALERS Stock
- News Eurobio Scientific
- Diaxonhit Announces Consolidated Earnings Results for the Full Year Ended December 31, 2013